Bharat Biotech

WHO in November last year issued an emergency use listing (EUL) for COVAXIN, adding to a growing portfolio of vaccines validated for the prevention of COVID-19 caused by SARS-CoV-2

"We're extremely pleased that we can proceed with our clinical trials for Covaxin our whole virus inactivated COVID-19 vaccine candidate," Dr Shankar Musunuri, CEO and Co-Founder, Ocugen Inc said

CEPI has till date announced funding for nine such projects including the Bharat Biotech one

A senior government official had told Business Standard last week that so far there was no scientific evidence to expand the vaccination programme to young children

Weeks after WHO suspended the supply of Covaxin through UN procurement agencies, the MEA suggested that Bharat Biotech addresses the issue immediately to avoid the cancellation

DCGI has granted emergency use authorisation for Biological E's Covid-19 vaccine Corbevax and Bharat Biotech's Covaxin

This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years

Covaxin has EUA in Mexico for use in adults; data submitted for EUA for children aged 2-18 years

WHO had earlier suspended the supply of Covaxin through US procurement agencies, after its inspectors identified GMP (good manufacturing practice) deficiencies in the Bharat Biotech's plants

Vaccine majors SII and Bharat Biotech said they have decided to cut prices of precaution dose of their respective Covid-19 vaccines to Rs 225 per shot for private hospitals after discussion with govt

SII and Bharat Biotech have been major suppliers of Covid-19 vaccines to the government so far

Various countries including Australia, have recognised Covaxin for facilitating travel

A recent ICMR study has shown that breakthrough cases after full vaccination with Covaxin have shown a significant increase in the immune response against coronavirus' variants of concern

Vaccination programme cannot lose govt attention

Bharat Biotech also said the WHO announcement will not impact the Ocugen trials

Bharat biotech says there are no issues with Covaxin or its certification, further we will focus on pending facility maintenance, has no supply commitments pending for UN agency.

The vaccine manufacturer has said that the company is slowing down the production of Covaxin for facility optimization.

This is to allow the manufacturer to upgrade facilities and address deficiencies found in an inspection

Bharat Biotech on Friday announced the temporary slowing down of production of COVAXIN across its manufacturing facilities

'For the coming period, the company will focus on pending facility maintenance, process and facility optimization activities,' the Hyderabad-based company said